Policy Issues for the Development and Use of Biomarkers in Health

  title={Policy Issues for the Development and Use of Biomarkers in Health},
  author={Rachael J. Ritchie and Marie-Ange Baucher},
  journal={China Biotechnology},
The OECD is a unique forum where governments work together to address the economic, social and environmental challenges of globalisation. The OECD is also at the forefront of efforts to understand and to help governments respond to new developments and concerns, such as corporate governance, the information economy and the challenges of an ageing population. The Organisation provides a setting where governments can compare policy experiences, seek answers to common problems, identify good… 
22 Citations

Figures and Tables from this paper

Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology
This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption, and urges a European evolution towards an initial minimum testing scenario.
Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine
The main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients are shown.
Tracing a roadmap for vitamin B12 testing using the health technology assessment approach
Tracing a roadmap for B12 testing by exploiting the HTA model to balance the stakeholders’ claims and maximizing the patient’s outcome may help to manage the marker demand.
Biorepositories and Biomarker Development: Regulatory Challenges
Changing regulatory conditions and the availability of various biorepositories paired with new European unequivocal provisions for CDx biomarker development and conformity assessment procedures for approval (CE-marking) may allow to develop biomarker performance characteristics and/or analytical/clinical validity even in the absence of contemporaneously sourced clinical trials specimen.
Measuring the chronology of the translational process of molecular genetic discoveries
It is concluded that new molecular genetic tests take significant time between discovery and clinical implementation, and that further work is needed to pinpoint key factors, including policy and organization factors, that may allow for improving and streamlining this process.
Immune biomarkers: the promises and pitfalls of personalized medicine
A conceptual overview of the field of immune biomarkers is provided and the progress made so far, as well as the future potential in the context of the scientific, logistical, financial, legal and ethical framework within which this research is being carried out and translated into clinical use are discussed.
Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
Clinicians see the adoption of NITs for NAFLD as a complex process that is modulated by several factors, such as robust evidence, practical guidelines, a proper payment system, and local champions, which are indicated as important facilitating factors.


Genetic tests and genomic biomarkers: regulation, qualification and validation.
This work states that there are still very few validated biomarkers of proven and robust clinical utility, and at present there is no established, standardized means for validating the association between a marker (or set of markers) and clinical outcomes.
Personalized Medicine and the Practice of Medicine in the 21st Century
  • A. Issa
  • Medicine, Political Science
    McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students
  • 2007
The role and increasing importance of personalized medicine in health care is described, as well as some of the ongoing challenges for integrating personalized medicine into contemporary medicine are discussed.
Keynote review: Is declining innovation in the pharmaceutical industry a myth?
The Case for Personalized Medicine
The case is made, through real-world examples, that personalized medicine is delivering significant value to individuals, to industry, and to the health care system overall and that it will continue to grow in importance if the authors can lift the barriers that impede its adoption and build incentives to encourage its practice.
Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib
Interestingly, many of the genes identified appear to be strongly related to reported mechanisms of BCR-ABL transformation and warrant additional research as potential drug targets.
Advances in Myeloma Genetics and Prospects for Pharmacogenomic Testing in Multiple Myeloma
  • J. Claudio, A. Stewart
  • Biology, Medicine
    American journal of pharmacogenomics : genomics-related research in drug development and clinical practice
  • 2005
Genetics and gene expression profiling technology have improved molecular-based patient stratification and prognostic staging, expanded knowledge of the molecular mechanism of chemotherapeutic agents, and provided a better understanding of myeloma bone disease, and the use of pharmacogenomic strategies in myelomas is already changing medical practice.
The price of innovation: new estimates of drug development costs.
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
  • M. Fukuoka, Yi-long Wu, T. Mok
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel and the predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis).
Preventing Chronic Diseases: A Vital Investment
A new book enPDFd preventing chronic diseases a vital investment to read is offered, offering you a new book to read and helping you to love reading.